Latest Asx News

Australian Rare Earths Limited (ASX, AR3) reported strong progress in its Koppamurra Rare Earths Project with high recovery rates and production milestones, while also expanding and resuming drilling at its Overland Uranium Project. The company bolstered its financial position through government grants and option exercises.

Terra Metals has reported multiple new zones of massive and semi-massive sulfide mineralisation at its Southwest Prospect within the Dante Project, signalling a potentially large-scale, multi-metal magmatic system. Assay results are pending as drilling and geophysical surveys continue.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

Adslot Ltd reports solid progress in Q1 FY26, highlighting growth in its StoreFront and Marketplace platforms alongside a successful $989,000 capital raise to fuel expansion.

Tyranna Resources has advanced its exploration and acquisition efforts in Angola, securing a major stake in the Chinguar Gold Project and extending its lithium-caesium project tenure, supported by a solid cash position.

Latrobe Magnesium successfully commissioned its Demonstration Plant producing magnesium oxide and secured $10 million in funding, while receiving a $200 million financing interest from the U.S. Export Import Bank for its next-stage commercial plant.

Fitzroy River Corporation reported steady royalty income for the June quarter and highlighted significant progress on several royalty projects, including government approvals for Buru Energy’s Rafael Gas Project and a major equity raise for Endura Mining’s Snowy River Gold development.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Carlton Investments reported a slight rise in net profit and an 8.7% increase in dividends for FY2025, while its investment portfolio grew nearly 60% over five years despite recent market fluctuations.